OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Talati on Rationale for Collecting Real-World Data on Venetoclax/HMA Combos in AML

July 8th 2020

Chetasi Talati, MD, discusses the design of a chart review study with venetoclax and hypomethylating agents in older patients with newly-diagnosed acute myeloid leukemia.

Dr. Hope on the Effectiveness of 68Ga-PSMA-11 PET in Prostate Cancer

July 8th 2020

Thomas A. Hope, MD, discusses the positive findings from a phase 3 imaging study, which utilized 68Ga-PSMA-11 PET in the detection of pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Dr. Shore on the Potential Utility of Relugolix in Advanced Prostate Cancer

July 8th 2020

Neal D. Shore, discusses the potential utility of relugolix in patients with advanced prostate cancer.

Dr. Salani on the Current State of Biomarker Testing in Cervical Cancer

July 8th 2020

Ritu Salani, MD, MBA, discusses the current state of biomarker testing in cervical cancer.

Dr. Blank on Adjuvant Versus Neoadjuvant Approaches in Stage III Melanoma

July 8th 2020

Christian U. Blank, MD, PhD, discusses adjuvant versus neoadjuvant approaches in macroscopic stage III melanoma.

Dr. Gupta on Challenges With Perioperative Immunotherapy in Bladder Cancers

July 8th 2020

Shilpa Gupta, MD, discusses challenges with perioperative immunotherapy in bladder cancer.

Dr. Litton on the EMBRACA Trial in Advanced BRCA1/2+ Breast Cancer

July 8th 2020

Jennifer K. Litton, MD, discusses the phase 3 EMBRACA trial in patients with germline BRCA1/2-mutated metastatic HER2-negative breast cancer.

Dr. Neelapu on Potential Advantages of Allogeneic CAR T-Cell Therapy in Lymphoma

July 7th 2020

Sattva Neelapu, MD, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.

Dr. Hoffman on Advantages of Self-Administration With PTG-300 in Polycythemia Vera

July 7th 2020

Ronald Hoffman, MD, discusses the advantages of self-administration with the investigational hepcidin mimetic PTG-300 for patients with polycythemia vera (PV).

Dr. Ruan on Unanswered Questions Regarding Treatment Decisions in MCL

July 7th 2020

Jia Ruan, MD, PhD, discusses some of the unanswered questions regarding optimizing treatment selection in patients with mantle cell lymphoma.

Dr. Braunstein on the Utility of Maintenance Therapy in Multiple Myeloma

July 7th 2020

Marc J. Braunstein, MD, PhD, discusses the utility of maintenance therapy in patients with multiple myeloma.

Dr. Siena on the Design of the DESTINY-CRC01 Trial in HER2+ Metastatic CRC

July 7th 2020

Salvatore Siena, MD, provides an overview of the DESTINY-CRC01 trial in DESTINY-CRC01 trial in HER2-positive metastatic colorectal cancer.

Dr. Chaft on Predictive Biomarkers in Lung Cancer

July 6th 2020

Jamie E. Chaft, MD, discusses predictive biomarkers in lung cancer.

Dr. Yee on the Utility of Isatuximab in Combination Therapy for Relapsed/Refractory Myeloma

July 6th 2020

Andrew Yee, MD, discusses the utility of isatuximab-irfc in relapsed/refractory multiple myeloma.

Dr. Munshi on Next Steps With Idecabtagene Vicleucel in R/R Multiple Myeloma

July 6th 2020

Nikhil C. Munshi, MD, discusses the next steps for research with idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Dr. Bach on the Rationale to Conduct a Systematic Review of ctDNA in CRC

July 6th 2020

Sander Bach, MD, PhD, discusses the rationale to conduct a systematic review of circulating tumor DNA in colorectal cancer.

Dr. Munshi on T-Cell Persistence With Ide-Cel in R/R Multiple Myeloma

July 6th 2020

Nikhil C. Munshi, MD, discusses T-cell persistence with idecabtagene vicleucel demonstrated in the phase 2 KarMMA trial in patients with relapsed /refractory multiple myeloma.

Dr. Davids on Rationale for Ibrutinib/Umbralisib Combo in R/R CLL and MCL

July 6th 2020

Matthew S. Davids, MD, MMSc, discusses the rationale for examining ibrutinib in combination with umbralisib in relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

Dr. Ghia on Updated ASCEND Trial Results in Relapsed/Refractory CLL

July 6th 2020

Paolo Ghia, MD, PhD, discusses updated results from the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Dr. Adams on the Utility of Combination CTLA-4 and PD-1 Blockade in Breast Cancer

July 6th 2020

Sylvia Adams, MD, discusses the utility of combining anti–CTLA-4 and anti–PD-1 agents in breast cancer.